Lisinopril
Product Images NDC 21695-345
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lisinopril (NDC 21695-345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Picture Of Lisinopril Table 1 (81210afd 6505 4d38 Ab83 E276ee4ce144 02)
This is a report presenting the incidence and discontinuation rates of adverse effects observed in controlled studies in patients receiving Tiiaaprl hydrochloratiazide. It lists a range of possible side effects and compares their incidence rates between two groups of patients. These include fatigue, asthenia, orthostatic effects, cardiovascular effects, digestive issues, musculoskeletal cramps, headaches, dizziness, coughing, upper respiratory infections, nasal congestion, among others.*
Picture Of Lisinopril Table 2 (81210afd 6505 4d38 Ab83 E276ee4ce144 03)
Picture Of Lisinopril Table 3 (81210afd 6505 4d38 Ab83 E276ee4ce144 04)
This appears to be a table showing the frequency of certain adverse events for patients receiving high dose and low dose treatment in clinical trials involving Evonts (possibly a drug with registration numbers He1568 and He1595). The adverse events listed include dizziness, hypotension, increased creatinine levels, hyperkalaemia, NPN (non-protein nitrogen) levels increased, and syncope. However, without further information or context, it is difficult to provide a more detailed description or interpretation of the data presented.*
Picture Of Lisinopril Table 4 (81210afd 6505 4d38 Ab83 E276ee4ce144 05)
This text appears to be describing dosing guidelines for medication based on the patient's renal function. It lists different levels of impairment and corresponding clearance rates and doses. It also includes a warning for potential allergic reactions during membrane exgosare for dialysis patients. The text suggests adjusting the dosage or dosing interval based on blood pressure response.*
Lisinopril 2.5mg (81210afd 6505 4d38 Ab83 E276ee4ce144 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.